Patent application number | Description | Published |
20110288601 | ELECTRICAL NERVE STIMULATION DEVICE - The electrical nerve stimulation unit in accordance with the present invention generally includes a housing, an input panel, a display panel, a controller, a first channel output, a second channel output, and a power system. While the device is generally described in terms of use as a TENS unit, it must be noted that other nerve stimulation applications for the device are envisioned as well. The myriad of intelligent and proactive programmable software functions and features of the present invention are executed on the controller's microprocessor. For instance, open lead monitoring, soft recovery implementation, compliance monitoring, and enhanced power management are all controlled and monitored through the interfacing of the processor with the various devices and hardware on the unit's hardware platform. | 11-24-2011 |
20110288616 | ELECTRICAL NERVE STIMULATION DEVICE - The electrical nerve stimulation unit in accordance with the present invention generally includes a housing, an input panel, a display panel, a controller, a first channel output, a second channel output, and a power system. While the device is generally described in terms of use as a TENS unit, it must be noted that other nerve stimulation applications for the device are envisioned as well. The myriad of intelligent and proactive programmable software functions and features of the present invention are executed on the controller's microprocessor. For instance, open lead monitoring, soft recovery implementation, compliance monitoring, and enhanced power management are all controlled and monitored through the interfacing of the processor with the various devices and hardware on the unit's hardware platform. | 11-24-2011 |
Patent application number | Description | Published |
20100237781 | WIRELESS CONVENIENCE LIGHTING SYSTEM AND METHOD OF MAKING SAME - A wireless convenience lighting system, comprises a base unit, the base unit connectable to an AC power supply, the base unit having a transmitter structure emitting at least one signal indicating one of an AC power loss or the AC power on, a remote lighting unit having a light source, and auxiliary power supply and a receiver structure, the receiver structure receiving the signal from the base unit, the base unit wirelessly activating the light source of the remote lighting unit when the AC power is lost. | 09-23-2010 |
20100237783 | WIRELESS CONVENIENCE LIGHTING SYSTEM AND METHOD OF MAKING SAME - A wireless convenience lighting system, comprises a base unit, the base unit connectable to an AC power supply, the base unit having a transmitter structure emitting at least one signal indicating one of an AC power loss or the AC power on, a remote lighting unit having a light source, and auxiliary power supply and a receiver structure, the receiver structure receiving the signal from the base unit, the base unit wirelessly activating the light source of the remote lighting unit when the AC power is lost. | 09-23-2010 |
Patent application number | Description | Published |
20120061510 | Aircraft Engine Exhaust Nozzle System for Jet Noise Reduction - The aircraft exhaust engine nozzle system includes a fan nozzle to receive a fan flow from a fan disposed adjacent to an engine disposed above an airframe surface of the aircraft, a core nozzle disposed within the fan nozzle and receiving an engine core flow, and a pylon structure connected to the core nozzle and structurally attached with the airframe surface to secure the engine to the aircraft. | 03-15-2012 |
20120061525 | Blended Cutout Flap for Reduction of Jet-Flap Interaction Noise - An aircraft system includes a wing and a trailing edge device coupled to the wing. The trailing edge device is movable relative to the wing, and includes a leading edge and a trailing edge having a center flap portion and a plurality of outer edge portions integrally combined with the center flap portion such that the center flap portion is shorter in width than that of outer edge portions. | 03-15-2012 |
20120068011 | Active Aircraft Pylon Noise Control System - An active pylon noise control system for an aircraft includes a pylon structure connecting an engine system with an airframe surface of the aircraft and having at least one aperture to supply a gas or fluid therethrough, an intake portion attached to the pylon structure to intake a gas or fluid, a regulator connected with the intake portion via a plurality of pipes, to regulate a pressure of the gas or fluid, a plenum chamber formed within the pylon structure and connected with the regulator, and configured to receive the gas or fluid as regulated by the regulator, and a plurality of injectors in communication with the plenum chamber to actively inject the gas or fluid through the plurality of apertures of the pylon structure. | 03-22-2012 |
20150232170 | Active Aircraft Pylon Noise Control System - An active pylon noise control system for an aircraft includes a pylon structure connecting an engine system with an airframe surface of the aircraft and having at least one aperture to supply a gas or fluid therethrough, an intake portion attached to the pylon structure to intake a gas or fluid, a regulator connected with the intake portion via a plurality of pipes, to regulate a pressure of the gas or fluid, a plenum chamber formed within the pylon structure and connected with the regulator, and configured to receive the gas or fluid as regulated by the regulator, and a plurality of injectors in communication with the plenum chamber to actively inject the gas or fluid through the plurality of apertures of the pylon structure. | 08-20-2015 |
Patent application number | Description | Published |
20100098638 | RIP140 Regulation of Diabetes - Inhibition of RIP140 increases glucose transport. Compounds that inhibit RIP140 expression or activity are useful for treating disorders associated with aberrant glucose transport (e.g., diabetes), treating obesity, increasing metabolism (e.g., fatty acid metabolism), and increasing brown fat. | 04-22-2010 |
20120208862 | RIP140 REGULATION OF GLUCOSE TRANSPORT - Inhibition of RIP140 increases glucose transport. Compounds that inhibit RIP140 expression or activity are useful for treating disorders associated with aberrant glucose transport (e.g., diabetes), treating obesity, increasing metabolism (e.g., fatty acid metabolism), and increasing brown fat. | 08-16-2012 |
20150111947 | COMPOSITIONS AND METHODS FOR DECREASING LEUKOCYTE EXTRAVASATION AND VESSEL FLUID LEAKAGE - Provided herein are methods of decreasing leukocyte extravasation from a lymph or blood vessel into a tissue in a mammal, methods of decreasing fluid leakage from a lymph or blood vessel in a mammal in need thereof, methods of decreasing formation of atherosclerotic plaques in a mammal in need thereof, and methods of treating atherosclerosis in a mammal that include administering to the mammal an oligonucleotide that decreases Mitogen-activated protein kinase kinase kinase kinase 4 (Map4k4) mRNA expression in an endothelial cell. Also provided are methods of identifying a candidate agent useful for decreasing leukocyte extravasation or decreasing fluid leakage from a lymph or blood vessel in a mammal, and compositions containing an oligonucleotide that decreases Map4k4 mRNA expression in an endothelial cell and additional therapeutic agents. | 04-23-2015 |
20150133520 | COMPOSITIONS AND METHODS FOR INDUCING MYOBLAST DIFFERENTIATION AND MYOTUBE FORMATION - Provided herein are methods of inducing differentiation of a mammalian myoblast into a mammalian myocyte that include contacting a mammalian myoblast with an oligonucleotide that decreases Mitogen-activated protein kinase kinase kinase kinase 4 (Map4k4) mRNA expression in a mammalian myoblast or myocyte. Also provided are methods of inducing mammalian myoblasts or myocytes to form a myotube that include contacting two or more mammalian myoblasts or two or more mammalian myocytes with an oligonucleotide that decreases Map4k4 mRNA expression in a mammalian myoblast or myocyte. Also provided are methods of identifying a candidate agent useful for inducing muscle formation, and compositions containing an oligonucleotide that decreases Map4k4 mRNA expression in mammalian myoblast or myocyte and one or more additional muscle therapeutic agents and/or muscle-building neutraceuticals. | 05-14-2015 |